Phase II Trial of Iodine-131 Anti-B1 Antibody for Previously Untreated, Advanced Stage, Low Grade Non-Hodgkin's Lymphoma.

Trial Profile

Phase II Trial of Iodine-131 Anti-B1 Antibody for Previously Untreated, Advanced Stage, Low Grade Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs Iodine-131 tositumomab; Tositumomab
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Jul 2012 Actual patient number changed from 76 to 77 as reported by ClinicalTrials.gov.
    • 03 Jul 2012 Primary endpoints identified as reported by ClinicalTrials.gov.
    • 20 Apr 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top